information about their effectiveness and how to obtain them is often incomplete, misleading, or taken out of context
The efficacy of semaglutide in controlling blood glucose levels and facilitating weight loss, along with the cardiovascular benefits demonstrated in the SUSTAIN-6 and PIONEER-6 trials, has expanded its clinical utility, potentially making it a first-line choice for many patients
The HK Vitals skincare range is formulated with targeted nutrients and scientifically backed ingredients that help cleanse, nourish, and hydrate the skin while supporting a naturally radiant, smooth, and youthful appearance
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach